MktsMarkets

Ovid Therapeutics Inc.
NASDAQ: OVIDKey statistics
OVID News
Stories mentioning OVID from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 718.00 | 132.00 | 6,272 | 130.00 | 76.00 | 173.00 | 169.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 11,181 | 6,588 | 5,870 | 6,465 | 6,659 | 5,933 | 7,855 | 12,582 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 17,846 | 13,011 | 12,655 | 11,345 | 12,680 | 10,801 | 13,399 | 20,686 |
| Operating Income (Loss) | (17,846) | (12,293) | (12,523) | (5,073) | (12,550) | (10,725) | (13,226) | (20,517) |
| Interest Income | 737.00 | 848.00 | 303.00 | 384.00 | 491.00 | 650.00 | 947.00 | 991.00 |
| Interest Expense | ||||||||
| Other Expense | 858.00 | 21,957 | 365.00 | 389.00 | 2,315 | 1,471 | (780.00) | 29,038 |
| Pretax Income | (16,988) | 9,663 | (12,158) | (4,684) | (10,235) | (9,254) | (14,006) | 8,521 |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (16,988) | 9,663 | (12,158) | (4,684) | (10,235) | (9,254) | (14,006) | 8,521 |
| Earnings Per Share (Basic) | (0.20) | 0.12 | ||||||
| Earnings Per Share (Diluted) | (0.20) | 0.12 | ||||||
| Weighted Average Shares Outstanding (Basic) | 70,976 | 70,916 | ||||||
| Weighted Average Shares Outstanding (Diluted) | 70,976 | 71,201 | ||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About OVID
Ovid Therapeutics Inc. (NASDAQ: OVID) is a stock listed on the Nasdaq Stock Market under the ticker symbol OVID. It last traded at $2.54 (Nov 13, 2026, 4:00 PM ET), down 0.4% on the day. That gives Ovid Therapeutics a market capitalisation of $479.4M.
Over the past 52 weeks OVID has traded between $1.18 and $3.10.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $17.0M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $0 | -$17.0M | — |
| Dec 31, 2025 | $718.0K | $9.7M | 1345.8% |
| Sep 30, 2025 | $132.0K | -$12.2M | -9210.6% |
| Jun 30, 2025 | $6.3M | -$4.7M | -74.7% |
From Ovid Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…